Outcomes from<unk>  are variable and depend on how severely an individual is affected (the WAS score may be used to assess disease severity). The milder end of the disease spectrum associated with the WAS gene is referred to as X-linked neutropenia or X-linked thrombocytopenia, and the latter is thought to have a normal life expectancy with reports of minimally affected males surviving into their seventh decade without treatment. Traditionally however<unk>  has been associated with premature death from causes including bleeding, infections, or malignancy.<unk>  is a condition with variable expressivity, meaning that even within the same family some may exhibit only chronic thrombocytopenia while others experience severe, life-threatening complications of<unk>  in infancy or childhood. Given symptoms often progress with age, it is challenging to predict how affected a newly diagnosed infant will eventually be. There is some genotype-phenotype correlation, with most individuals with X-linked thrombocytopenia having missense variants in the WAS gene versus 86.5% of those that make no WAS protein having the classic<unk>  phenotype. Overall the prognosis for individuals with<unk>  has improved considerably over the past decades due to earlier diagnoses and more access to treatments.
Wiskott–Aldrich syndrome
Common variable immunodeficiency
Chronic granulomatous disease
Severe combined immunodeficiency
SAPHO syndrome
Hyper-IgM syndrome type 5
Ataxia–telangiectasia
Hyper-IgM syndrome type 2